Sales Proceeds Partially Donated: Book Release on Cat Longevity Research — 'Research on AIM: The Journey to the World's First Medicine for Cats to Live Longer' (Gakken Science Books)
NQ Score
87/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Gakken Inc., a subsidiary of Gakken Holdings, released the science book 'Research on AIM: The Journey to the World's First Medicine for Cats to Live Longer' on June 4, 2026. A portion of sales will be donated to support research on a cat kidney disease treatment developed by Dr. Tooru Miyazaki of the AIM Medical Research Institute.
AI Analysis
Frequently Asked Questions
- Q: Who is 'Research on AIM' intended for?
- A: Cat lovers, general readers interested in science, and educators. Written accessibly for middle school level and above.
- Q: What is the supervisor's background?
- A: Dr. Tooru Miyazaki is an immunology expert, former University of Tokyo professor, and discoverer of AIM protein.
- Q: How will the donations be used?
- A: Part of sales will support clinical trials and regulatory approval processes for the cat kidney disease treatment.
- Q: Where can I read the e-book?
- A: Available on Kindle and Rakuten Kobo. DRM-free format readable on smartphones, tablets, and PCs.
- Q: What's unique about this series?
- A: Realistic portrayal of scientific research, including struggles and failures, highlighting researchers' human sides.